# DESCRIPTION

## TECHNICAL FIELD

- introduce KRAS oncogene activation

## BACKGROUND ART

- describe RAS proteins
- explain RAS isoforms and mutations
- discuss limitations of current RAS inhibitors

## DISCLOSURE OF INVENTION

- introduce flavagline derivatives as KRAS inhibitors

### R8 is —H, —OCH3, —Br, —F, —Cl;

- describe flavagline derivatives' structure

### R8 is —H, —OCH3, —Br, —F, —Cl;

- describe pharmaceutical composition

## MODES FOR CARRYING OUT THE INVENTION

- demonstrate in vitro effects of flavagline derivatives
- demonstrate in vivo effects of flavagline derivatives
- describe materials and methods used in experiments
- detail specific experimental procedures and assays

